Ampio's Ampion meets in latest Phase III OA trial

Ampio Pharmaceuticals Inc. (NYSE-M:AMPE) said Ampion met the primary endpoint in the Phase III AP-003-C trial to treat severe osteoarthritis (OA) of the knee. Ampio hopes to meet with FDA next quarter, after which the company plans to submit a BLA for Ampion to treat signs and symptoms of severe OA of the knee.

Ampion has previously met the primary endpoint in the Phase III SPRING trial to treat OA of the knee, but missed the primary endpoint in the Phase III STRIDE and PIVOT trials in the indication (see BioCentury, Aug. 19, 2013; April 27, 2015 & July 11, 2016)...